Literature DB >> 12443825

Gram-negative bacteria and phagocytic cell interaction mediated by complement receptor 3.

José Agramonte-Hevia1, Aliesha González-Arenas, Diana Barrera, Marco Velasco-Velázquez.   

Abstract

Complement receptor 3 (CR3) is an integrin that recognizes several different ligands. Binding to CR3 in phagocytic cells activates signaling pathways involved in cytoskeleton rearrangement, regulation of cell motility, alteration of gene expression and phagocytosis of complement-opsonized as well as of some non-opsonized particles and pathogenic bacteria. However, CR3-mediated phagocytosis of some Gram-negative bacteria does not induce bacterial clearance. Pseudomonas aeruginosa, Salmonella and Escherichia coli are eliminated after phagocytic cell-bacteria interaction mediated by CR3. However, Bordetella takes advantage of the CR3 function and uses it to enter into macrophages leading to bacterial survival. The final fate of the pathogen is determined by combinations of host and bacterial factors, in which molecular interactions between CR3 and bacterial ligands are involved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443825     DOI: 10.1111/j.1574-695X.2002.tb00640.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  17 in total

1.  Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  Paula S Mobberley-Schuman; Alison A Weiss
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 2.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  The myeloid differentiation factor 88 is dispensable for the development of a delayed host response to Pseudomonas aeruginosa lung infection in mice.

Authors:  M R Power; J S Marshall; M Yamamoto; S Akira; T-J Lin
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

4.  Differential infection of mononuclear phagocytes by Francisella tularensis: role of the macrophage mannose receptor.

Authors:  Grant S Schulert; Lee-Ann H Allen
Journal:  J Leukoc Biol       Date:  2006-06-30       Impact factor: 4.962

Review 5.  Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.

Authors:  William J Janssen; Adrianne L Stefanski; Bruce S Bochner; Christopher M Evans
Journal:  Eur Respir J       Date:  2016-09-01       Impact factor: 16.671

6.  Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria.

Authors:  Haim Tsubery; Hertzig Yaakov; Sofia Cohen; Tal Giterman; Ariella Matityahou; Mati Fridkin; Itzhak Ofek
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Authors:  Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

8.  Phagocytosis inhibits F-actin-enriched membrane protrusions stimulated by fractalkine (CX3CL1) and colony-stimulating factor 1.

Authors:  Yong Luo; Beth M Isaac; Arturo Casadevall; Dianne Cox
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

9.  The adhesion GPCR BAI1 mediates macrophage ROS production and microbicidal activity against Gram-negative bacteria.

Authors:  Emily A Billings; Chang Sup Lee; Katherine A Owen; Ryan S D'Souza; Kodi S Ravichandran; James E Casanova
Journal:  Sci Signal       Date:  2016-02-02       Impact factor: 8.192

10.  Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans.

Authors:  Chiara Luberto; Beatriz Martinez-Mariño; Daniel Taraskiewicz; Benjamin Bolaños; Pasquale Chitano; Dena L Toffaletti; Gary M Cox; John R Perfect; Yusuf A Hannun; Edward Balish; Maurizio Del Poeta
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.